Cost of heart drugs makes US patients skip pills, Mayo research reveals

31 March 2011

For more than five million Americans with heart failure, a critical step to better health is taking the medications they are prescribed. But many patients fail to do so, putting themselves at greater risk of hospitalization and even death.

To date, studies have not fully answered why patients fall short when it comes to taking heart medicine. In a study appearing in the April issue of Mayo Clinic Proceedings, Mayo Clinic researchers found the drugs’ cost is one of the biggest deterrents. “We found patients weren’t filling their prescriptions because of the expense,” says Shannon Dunlay, Mayo Clinic cardiologist and lead author of the study.

The study recruited patients from Olmsted County, Minnesota, and tracked their pharmacy records. Previous studies looked only at electronic prescription claims data, possibly missing drugs purchased with cash or not covered by insurance, Dr Dunlay says. The 209 patients in the study, aged 60 to 86, were asked how often they missed doses or did not take drugs at all, and why.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical